$ZLAB

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

Zai Lab Ltd (ZLAB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. © 2026. Zai Lab. All Rights Reserved.NASDAQ:ZLAB | HKEX:9688 Advancing First- and Best-in- Class Therapies in Oncology and Immunology October 2026 Forward-Looking Statements 2 Forward-Looking Statements This presentation contains forward-looking statements, including statements r

Zai Lab (ZLAB) will present Phase 1/1b trial data for ZL-1503, an experimental eczema treatment, at ACAAI 2026. The data, from healthy volunteers, includes pharmacokinetic and pharmacodynamic results. ZL-1503 targets IL-13 and IL-31, aiming to provide rapid itch relief and reduce inflammation. An investor conference call is scheduled for November 13, 2026.

Cantor Fitzgerald reiterated an Overweight rating and $37 price target for Zai Lab (ZLAB), citing potential for its DLL3 ADC, zocilurtatug, in small cell lung cancer. The stock is up 45% year-to-date. Zai Lab's Q2 earnings beat expectations with $106.3M revenue and adjusted EPS of -$0.05. Analysts maintain a Strong Buy consensus with price targets ranging from $24.25 to $50.

Zai Lab (ZLAB) will present global clinical trial data on zocilurtatug pelitecan (zoci) for first-line extensive-stage small cell lung cancer (ES-SCLC) at ESMO Congress 2026. The trial evaluates zoci in combination with atezolizumab with or without carboplatin. An investor call is scheduled for October 23, 2026, to discuss the data and future plans. Zai Lab highlights zoci's potential as a backbone ADC in ES-SCLC treatment.

Zai Lab (ZLAB) and Argenx reported positive Phase 3 results for VYVGART Hytrulo in treating autoimmune myositis, showing significant improvements over placebo. The data suggest potential for the drug in a market currently dominated by corticosteroids. Analysts highlight the importance of execution on recent launches and China's pricing pressures. Some analysts predict modest revenue growth and continued losses by 2029.

Argenx (ARGX) and Zai Lab (ZLAB) reported positive Phase 3 results for VYVGART Hytrulo in autoimmune myositis. ARGX saw a 15% stock rise and a $1,100 price target from RBC. ARGX reported Q2 2026 revenue of $1.516B, up 60% YoY, while ZLAB reported $106.3M revenue, down 3% YoY. ARGX has a stronger financial position with $5.2B in cash, while ZLAB has $717.5M. Investors should watch FDA decisions and ZLAB's commercial execution.

Zai Lab (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) reported positive topline Phase 3 ALKIVIA results for efgartigimod (VYVGART Hytrulo) in autoimmune myositis. The study met the Week 52 primary endpoint in the combined IMNM and DM population (p=0.0011), with mean Total Improvement Score 47.95 vs 32.56 vs placebo. IMNM also met (p=0.0048); DM did not reach significance (p=0.1093).

Zai Lab (ZLAB) reported Q2 2026 revenues of $106.3 million, down from $110.0 million a year earlier. Net product revenue was $105.8 million, up 11% sequentially, with growth tied to VYVGART and stabilization of ZEJULA. Net loss was $50.8 million ($0.05/share). Cash was $717.5 million at June 30, 2026. Management discussed Zoci and VYVGART timelines and supply constraints.

Zai Lab Limited (NASDAQ:ZLAB) reported quarterly results with revenue of about $106m, 2.4% above analyst forecasts, and statutory loss of $0.46 per share, 2.4% smaller than expected. For 2026, 16 analysts’ consensus calls for revenue $422.9m (down from $447.6m) and loss $2.26 per share. Consensus price target stays near $32.18.